ClinicalTrials.gov
ClinicalTrials.gov Menu

Hyper-CVAD Treatment in Lymphoblastic Lymphoma (LBL-CISL-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01813344
Recruitment Status : Unknown
Verified March 2013 by Seong Hyun Jeong, Ajou University School of Medicine.
Recruitment status was:  Recruiting
First Posted : March 19, 2013
Last Update Posted : March 19, 2013
Sponsor:
Information provided by (Responsible Party):
Seong Hyun Jeong, Ajou University School of Medicine

Brief Summary:
Treatment outcomes of lymphoblastic lymphoma (LBL) have improved by the use of the regimens for acute lymphoblastic leukemia. Hyper-CVAD is one of the most effective treatments with high remission rate in acute lymphoblastic leukemia (ALL) and LBL. However, the treatment outcome of hyper-CVAD in LBL has reported only in small number of patients from single institution. The investigators conducted this study to evaluate the hyper-CVAD regimen based treatment in LBL.

Condition or disease
Lymphoblastic Lymphoma

Detailed Description:
We will analyze treatment outcome of lymphoblastic lymphoma patients treated with hyper-CVAD regimen from 13 institutions in Korea. In all patients, hyper-CVAD was initial treatment. After achievement of response, patients either underwent hematopoietic stem cell transplantation (HSCT) or consolidation with hyper-CVAD.

Study Type : Observational
Estimated Enrollment : 50 participants
Time Perspective: Retrospective
Official Title: The Clinical Outcomes of Hyper-CVAD Treatment in Lymphoblastic Lymphoma
Study Start Date : January 2012
Estimated Primary Completion Date : June 2013





Primary Outcome Measures :
  1. Overall survival [ Time Frame: 3-year ]
  2. Progression free survival [ Time Frame: 3-year ]

Secondary Outcome Measures :
  1. Response Rate [ Time Frame: 24 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult lymphoblast lymphoma patients treated with hyper-CVAD regimen in Korea
Criteria

Inclusion Criteria:

  • age over 18 at diagnosis
  • Pathologically proven lymphoblastic lymphoma

Exclusion Criteria:

  • proven HIV infection
  • pretreatment with other regimens

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01813344


Contacts
Contact: Seong Hyun Jeong, MD +82-31-219-5989 seonghyunmd@naver.com

Locations
Korea, Republic of
Ajou Universtiy School of Medicine Recruiting
Suwon, Kyeonggi, Korea, Republic of, 443-721
Contact: Geum Sook Jeong, MS    +82-31-219-5990    geumsook@ajou.ac.kr   
Sponsors and Collaborators
Ajou University School of Medicine

Responsible Party: Seong Hyun Jeong, Assistant professor, Ajou University School of Medicine
ClinicalTrials.gov Identifier: NCT01813344     History of Changes
Other Study ID Numbers: LBL-CISL-1
First Posted: March 19, 2013    Key Record Dates
Last Update Posted: March 19, 2013
Last Verified: March 2013

Keywords provided by Seong Hyun Jeong, Ajou University School of Medicine:
Adult lymphoblastic lymphoma
Hyper-CVAD
first-line treatment

Additional relevant MeSH terms:
Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, Lymphoid
Leukemia